Designing the Next Generation of
Psycho-Targeted Biotherapeutics
IP Protected Bio synthetic pathway for candidate production
Ability to Manufacture and conduct invitro & invivo efficacy testing and conduct human clinical trial
Portfolio of psycho-targeted biotherapeutics
Kahner Global’s Cannabis & Psychedelics Investment Summit Honors Evan Levine and PsyBio Therapeutics with Best Pitch Award
The Kahner Global’s Cannabis & Psychedelics Investment Summit is an annual conference that brings together some of the most influential leaders in the cannabis and psychedelics industries. At the latest summit in Miami on February 27, 2023, attendees had the opportunity to hear from experts on a variety of topics, including regulatory developments, emerging trends, and innovative new technologies.
Evan Levine, CEO & Founder of PsyBio Therapeutics, won Best Pitch with his visionary approach to developing next-generation therapies for mental health conditions using cutting-edge research and development methods. The win solidified PsyBio Therapeutics’ position as a leading player in the emerging field of psychedelic medicine, and the event provided a valuable platform for showcasing groundbreaking work and connecting with key players in the industry.
Psybio Was Formed to Create Psycho-targeted Biotherapeutics
Over 50 Years of Combined Leadership in the Biotech Industry
Clinical Trial Design, Approval, Execution, and Analysis Expertise
Regulatory Pathway, Intellectual Property, and Manufacturing Skills
